Xenon Pharmaceuticals Inc.

Equities

XENE

CA98420N1050

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
40.5 ^USD	+1.00%		+1.55%	-12.07%

Apr. 19	Xenon Pharmaceuticals Inc. Announces Board Resignations	CI
Mar. 11	Transcript : Xenon Pharmaceuticals Inc. Presents at Leerink Partners Global Biopharma Conference 2024, Mar-11-2024 11:20 AM

Xenon Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023

February 29, 2024 at 04:36 pm EST

Xenon Pharmaceuticals Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 182.39 million compared to USD 125.37 million a year ago. Basic loss per share from continuing operations was USD 2.73 compared to USD 2.06 a year ago.

Latest news about Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals Inc. Announces Board Resignations	Apr. 19	CI
Transcript : Xenon Pharmaceuticals Inc. Presents at Leerink Partners Global Biopharma Conference 2024, Mar-11-2024 11:20 AM	Mar. 11
Xenon Pharmaceuticals Insider Sold Shares Worth $330,290, According to a Recent SEC Filing	Mar. 08	MT
Xenon Pharmaceuticals Insider Sold Shares Worth $601,615, According to a Recent SEC Filing	Mar. 08	MT
Needham Adjusts Price Target on Xenon Pharmaceuticals to $62 From $50, Maintains Buy Rating	Mar. 01	MT
RBC Trims Price Target on Xenon Pharmaceuticals to $55 From $56, Keeps Outperform, Speculative Risk	Mar. 01	MT
Wedbush Raises Xenon Pharmaceuticals' PT to $51 From $46, Continues to See XEN1101 as Differentiated Asset; Maintains Outperform Rating	Mar. 01	MT
Xenon Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 29	CI
Xenon Pharmaceuticals Q4 Net Loss Widens	Feb. 29	MT
Transcript : Xenon Pharmaceuticals Inc., Q4 2023 Earnings Call, Feb 29, 2024	Feb. 29
Xenon Pharmaceuticals Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 29	CI
Certain Common Shares of Xenon Pharmaceuticals Inc. are subject to a Lock-Up Agreement Ending on 27-FEB-2024.	Feb. 26	CI
Certain Warrants of Xenon Pharmaceuticals Inc. are subject to a Lock-Up Agreement Ending on 27-FEB-2024.	Feb. 26	CI
Certain Options of Xenon Pharmaceuticals Inc. are subject to a Lock-Up Agreement Ending on 27-FEB-2024.	Feb. 26	CI
Transcript : Xenon Pharmaceuticals Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-08-2024 09:00 AM	Jan. 08
Citigroup Initiates Xenon Pharmaceuticals With Buy Rating, Price Target is $62	Jan. 04	MT
Stifel Adjusts Price Target on Xenon Pharmaceuticals to $62 From $53, Maintains Buy Rating	Dec. 18	MT
Xenon Pharmaceuticals Insider Sold Shares Worth $758,983, According to a Recent SEC Filing	Dec. 15	MT
Baird Initiates Xenon Pharmaceuticals With Outperform Rating, Price Target is $63	Dec. 08	MT
Sector Update: Health Care Stocks Gain Premarket Thursday	Nov. 30	MT
Xenon Pharmaceuticals Prices $300 Million Public Offering of Common Stock, Pre-Funded Warrants	Nov. 30	MT
Xenon Pharmaceuticals Launches $225 Million Public Offering	Nov. 29	MT
RBC Adjusts Xenon Pharmaceuticals' Price Target to $56 From $51, Maintains Outperform Rating	Nov. 28	MT
Xenon Pharmaceuticals Says Trial of Depression Drug Failed to Meet Primary Endpoint	Nov. 27	MT
Transcript : Xenon Pharmaceuticals Inc. - Special Call	Nov. 27

Chart Xenon Pharmaceuticals Inc.

Duration

Period

More charts

Company Profile

Xenon Pharmaceuticals Inc. is a Canada-based clinical-stage biopharmaceutical company focused on developing therapeutics to improve the lives of patients with neurological disorders, with a focus on epilepsy. The Companyâs product pipeline includes XEN1101 (Focal Onset Seizures), XEN1101 (Primary Generalized Tonic-Clonic Seizures), XEN1101 (Major Depressive Disorder) and NBI-921352 (NEUROCRINE). It is developing XEN1101, a differentiated Kv7 potassium channel opener, for the treatment of epilepsy, MDD and potentially other neurological disorders. Its XEN1101 Phase III epilepsy program includes two identical Phase III clinical trials, called X-TOLE2 and X-TOLE3, that are designed closely after the Phase IIb X-TOLE clinical trial. Its Phase III X-ACKT clinical trial is intended to support potential regulatory submissions in an additional epilepsy indication of primary generalized tonic-clonic seizures (PGTCS).

Sector

Biotechnology & Medical Research

Calendar

2024-05-06 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

40.5 USD

Average target price

57.44 USD

Spread / Average Target

+41.83%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
XENON PHARMACEUTICALS INC.	-12.07%	3.06B
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+0.73%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-8.42%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.73B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs